Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    纯度: >98.00%

    Neihulizumab(ALTB-168)是一种免疫检查点激动性抗体,与人CD162(PSGL-1)结合,导致活化T细胞下调。

  • GC72380 structure
    GC72380Vobarilizumab
    CAS: 1628814-88-9
    纯度: >97.00%

    Vobarilizumab(ALX-0061)是一种抗IL-6R单克隆抗体(mAb)(Kd:0.19 pM)。

  • GC72381 structure
    GC72381Sonelokimab
    CAS: 1414386-05-2
    纯度: >99.00%

    Sonelokimab(ALX 0761;M 1095)是一种三价纳米体,由单价骆驼科动物衍生的纳米体组成,对人白细胞介素(IL)-17A、IL-17F和人血清白蛋白VHH具有特异性。

  • GC72390 structure
    GC72390Anrukinzumab
    CAS: 910649-32-0
    纯度: >98.00%

    Anrukinzumab(IMA-638)是一种人源化的抗IL-13单克隆抗体。

  • GC72391 structure
    GC72391Avdoralimab
    CAS: 2226393-85-5
    纯度: >95.00%

    Avdoralimab(IPH 5401)是一种全人IgGκ单克隆抗体,靶向补体C5a受体1(C5aR1),阻止其与C5a结合。

  • GC72396 structure
    GC72396Cendakimab
    CAS: 2151032-62-9
    纯度: >99.00%

    Cendakimab(RPC4046;ABT 308;CC-93538)是一种针对IL-13分子的选择性人源化重组单克隆抗体。

  • GC72397 structure
    GC72397Ziltivekimab
    CAS: 2226654-05-1
    纯度: >99.00%

    Ziltivekimab(COR-001)是一种有效降低血清CRP的人抗IL-6单克隆抗体。

  • GC72415 structure
    GC72415Goflikicept
    CAS: 2416984-26-2
    纯度: >98.00%

    Goflikicept(RPH 104)是一种杂交蛋白,可选择性结合并灭活循环中的IL-1β和IL-1α。

  • GC72418 structure
    GC72418Inolimomab
    CAS: 152981-31-2
    纯度: >98.00%

    Inolimomab是一种抗白细胞介素-2受体(IL-2R) α链单克隆抗体。

  • GC72424 structure
    GC72424Lutikizumab
    CAS: 1791411-57-8
    纯度: >96.00%

    Lutikizumab (ABT-981)是一种抗il -1α和IL-1β双可变结构域免疫球蛋白。

  • GC72426 structure
    GC72426Manfidokimab
    CAS: 2428381-56-8
    纯度: 95.00%

    Manfidokimab (AK120)是一种抗白细胞介素4受体α (IL-4Rα) IgG4单克隆抗体。

  • GC72428 structure
    GC72428Melrilimab
    CAS: 2222865-46-3
    纯度: >96.00%

    Melrilimab(GSK 3772847)是一种IgG2κ抗IL1RL1/ST2/IL33R/DER4/FIT-1单克隆抗体。

  • GC72429 structure
    GC72429Mirikizumab
    CAS: 1884201-71-1
    纯度: >98.00%

    Mirikizumab(LY3074828)是一种人源化IgG4单克隆抗体,靶向白细胞介素23的p19亚基。

  • GC72433 structure
    GC72433Nemvaleukin alfa
    CAS: 2315268-27-8
    纯度: >99.00%

    Nemvaleukin alfa (ALKS 4230)是一种IL-2融合蛋白,可选择性结合中等亲和力的IL-2R。

  • GC72456 structure
    GC72456Eblasakimab
    CAS: 2445460-16-0
    纯度: >99.00%

    Eblasakimab (ASLAN004;CSL-334)是一种特异性靶向IL13RA1的人IgG4抗体,主要由CHO-K1细胞表达。

  • GC72471 structure
    GC72471Remtolumab
    CAS: 1791410-27-9
    纯度: >99.00%

    Remtolumab (ABT-122)是一种双变量结构域免疫球蛋白,可中和肿瘤坏死因子α (TNFα)和IL-17A。

  • GC72473 structure
    GC72473Crovalimab
    CAS: 1917321-26-6
    纯度: >98.00%

    Crovalimab(SKY59;RO7112689)是一种新型的人源化C5抗体,具有pH依赖性,在pH 7.4和5.8时的KD分别为15.2 nM和16.8μM。

  • GC72511 structure
    GC72511L-Cystathionine dihydrochloride
    CAS: 61125-50-6
    纯度: >99.50%

    L-Cystathionine dihydrochloride是一种非蛋白硫醚,是与含硫氨基酸代谢状态相关的关键氨基酸。

  • GC72573 structure
    GC72573Sodium 2-oxopropanoate-13C
    CAS: 124052-04-6
    纯度: >98.50%

    Sodium 2-oxopropanoate-13C是13C标记的2-氧丙酸钠。

  • GC72574 structure
    GC725742-Oxopropanoate-13C5 sodium
    CAS: 89196-78-1
    纯度: 不显示

    2-Oxopropanoate-13C5 sodium是13C标记的2-氧丙酸钠。

  • GC72575 structure
    GC72575L-Glutamic acid monosodium (hydrate)
    CAS: 6106-04-3
    纯度: >98.00%

    L-Glutamic acid monosodium (hydrate)是一种营养添加剂和调味剂。

  • GC72610 structure
    GC72610Cartap hydrochloride
    CAS: 15263-52-2
    纯度: >90.00%

    Cartap hydrochloride一种有机氮杀虫剂,可在分离的小鼠和兔膈神经膈肌中引起明显的不可逆钙依赖性挛缩。

  • GC72755 structure
    GC72755Tempol-d17,15N
    CAS: 90429-66-6
    纯度: 不显示

    Tempol-d17,15N是氘标记的Tempol。

  • GC72757 structure
    GC72757SPC 839
    CAS: 219773-55-4
    纯度: >99.00%

    SPC 839(化合物10)是一种口服活性的AP-1和NF-kB介导的转录激活抑制剂,IC50为0.008 μM。